These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 38657201)
21. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study. Martin TG; Moreau P; Usmani SZ; Garfall A; Mateos MV; San-Miguel JF; Oriol A; Nooka AK; Rosinol L; Chari A; Karlin L; Krishnan A; Bahlis N; Popat R; Besemer B; Martínez-López J; Delforge M; Trancucci D; Pei L; Kobos R; Fastenau J; Gries KS; van de Donk NWCJ Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):194-202. PubMed ID: 38052709 [TBL] [Abstract][Full Text] [Related]
22. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy. Hamadeh IS; Shekarkhand T; Rueda C; Firestone RS; Wang AX; Korde N; Hultcrantz ML; Lesokhin AM; Mailankody S; Hassoun H; Shah UA; Maclachlan K; Rajeeve S; Patel D; Shah GL; Scordo M; Lahoud OB; Chung DJ; Landau HJ; Giralt S; Usmani SZ; Tan CR Blood Adv; 2024 Jun; 8(12):3038-3044. PubMed ID: 38598713 [TBL] [Abstract][Full Text] [Related]
23. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583 [TBL] [Abstract][Full Text] [Related]
24. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma. Moore DC; Granger K; Hill H; Karabinos A; Davis JA Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927 [No Abstract] [Full Text] [Related]
25. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Cho SF; Anderson KC; Tai YT Front Immunol; 2018; 9():1821. PubMed ID: 30147690 [TBL] [Abstract][Full Text] [Related]
26. Teclistamab: First Approval. Kang C Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205 [TBL] [Abstract][Full Text] [Related]
27. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Riedhammer C; Bassermann F; Besemer B; Bewarder M; Brunner F; Carpinteiro A; Einsele H; Faltin J; Frenking J; Gezer D; Goldman-Mazur S; Hänel M; Hoegner M; Kortuem KM; Krönke J; Kull M; Leitner T; Mann C; Mecklenbrauck R; Merz M; Morgner A; Nogai A; Raab MS; Teipel R; Wäsch R; Rasche L Leukemia; 2024 Feb; 38(2):365-371. PubMed ID: 38245601 [TBL] [Abstract][Full Text] [Related]
28. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333 [TBL] [Abstract][Full Text] [Related]
29. FDA Approval Summary: Teclistamab - A Bispecific CD3 T-cell Engager for Patients with Relapsed or Refractory Multiple Myeloma. Baines AC; Kanapuru B; Zhao J; Price LSL; Zheng N; Konicki R; Manning ML; Gehrke BJ; Theoret MR; Gormley NJ Clin Cancer Res; 2024 Oct; ():. PubMed ID: 39412823 [TBL] [Abstract][Full Text] [Related]
30. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669 [TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909 [TBL] [Abstract][Full Text] [Related]
32. Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. Hua G; Scanlan R; Straining R; Carlson DS J Adv Pract Oncol; 2023 Mar; 14(2):163-171. PubMed ID: 37009408 [TBL] [Abstract][Full Text] [Related]
33. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210 [TBL] [Abstract][Full Text] [Related]
34. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662 [TBL] [Abstract][Full Text] [Related]
35. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast. Costa LJ; Rodriguez-Otero P Adv Ther; 2024 Aug; 41(8):3017-3027. PubMed ID: 38642197 [TBL] [Abstract][Full Text] [Related]
36. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. Zhao J; Ren Q; Liu X; Guo X; Song Y J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597 [TBL] [Abstract][Full Text] [Related]
37. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Shah N; Chari A; Scott E; Mezzi K; Usmani SZ Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000 [TBL] [Abstract][Full Text] [Related]
38. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Oliver-Caldes A; Español-Rego M; Zabaleta A; González-Calle V; Navarro-Velázquez S; Inogés S; de Cerio AL; Cabañas V; López-Muñoz N; Rodríguez-Otero P; Reguera JL; Moreno DF; Martínez-Cibrian N; López-Corral L; Pérez-Amill L; Martin-Antonio B; Rosiñol L; Cid J; Tovar N; Sáez-Peñataro J; López-Parra M; Olesti E; Guillén E; Varea S; Rodríguez-Lobato LG; Battram AM; González MS; Sánchez-Salinas A; González-Navarro A; Ortiz-Maldonado V; Delgado J; Prósper F; Juan M; Martínez-López J; Moraleda JM; Mateos MV; Urbano-Ispizua Á; Paiva B; Pascal M; Fernández de Larrea C Clin Cancer Res; 2024 May; 30(10):2085-2096. PubMed ID: 38466644 [TBL] [Abstract][Full Text] [Related]
39. Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. Girgis S; Lin SXW; Pillarisetti K; Banerjee A; Stephenson T; Ma X; Shetty S; Yang TY; Hilder BW; Jiao Q; Hanna B; Adams HC; Sun YN; Sharma A; Smit J; Infante JR; Goldberg JD; Elsayed Y Target Oncol; 2022 Jul; 17(4):433-439. PubMed ID: 35749004 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q Front Immunol; 2021; 12():720571. PubMed ID: 34421924 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]